Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Sclerosis, Secondary Progressive: early-phase trial registry
5 of 10 indexed Multiple Sclerosis, Secondary Progressive trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Multiple Sclerosis, Secondary Progressive: 10 US clinical trials tracked, 5 recruiting.
Multiple Sclerosis, Secondary Progressive is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Shirley Ryan AbilityLab, running 4 of these trials.
Enrollment posture brief
Registry condition multiple-sclerosis-secondary-progressive
OPEN 5 | RECR 50% | LATE 0 | EARLY 5 | RANK #1724 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Multiple Sclerosis, Secondary Progressive lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Sclerosis, Secondary Progressive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Sclerosis, Secondary Progressive is recruiting above its size-band peers.
5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Multiple Sclerosis, Secondary Progressive research.
Shirley Ryan AbilityLab accounts for 4 of 10 trials (40%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Multiple Sclerosis, Secondary Progressive trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.
-
Multiple Sclerosis, Secondary Progressive research is mostly interventional.
8 interventional and 2 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
MS-ResearchBiomarkerS
Cedars-Sinai Medical Center
NCT05204459
Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis
Shirley Ryan AbilityLab
NCT06516458
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
Shirley Ryan AbilityLab
NCT06390930
Intermittent Hypoxia in Persons With Multiple Sclerosis
Shirley Ryan AbilityLab
NCT06276634
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
Stanford University
NCT06138132
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
Kyverna Therapeutics
NCT06384976
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
Emmanuelle Waubant, MD PhD
NCT05122559
The Synergistic Effects of AIH and FES in Persons With MS
Shirley Ryan AbilityLab
NCT06413602
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
Johns Hopkins University
NCT02988401
Novel Imaging Markers in SPMS
University of Utah
NCT05357833
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Sclerosis, Secondary Progressive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Sclerosis, Secondary Progressive trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Sclerosis, Secondary Progressive page
10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Multiple Sclerosis, Secondary Progressive trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Shirley Ryan AbilityLab sponsors the most Multiple Sclerosis, Secondary Progressive trials on record, review their full trial history before evaluating a specific study. See Shirley Ryan AbilityLab's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Sclerosis, Secondary Progressive condition card totals 10 registered trials; most-linked intervention Acute Intermittent Hypoxia; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.